What’s Propelling Nightstar Therapeutics plc (NITE) to Decrease? The Stock Formed a Bearish Ascending Triangle Chart Pattern

May 17, 2018 - By Ann Prendergast

The stock of Nightstar Therapeutics plc (NITE) formed an ascending triangle with $12.75 target or 9.00 % below today’s $14.01 share price. The 9 months triangle pattern indicates high risk for the $404.96 million company. If the $12.75 price target is reached, the company will be worth $36.45M less.
The ascending triangle is a questionable performer despite its reputation as a reliable chart pattern. The ascending triangle has break even failure rate for up and down breakouts of 13% and 11%, respectively. The average rise and decline is 35% and 19%. The throwback or so called pullback rates are: 57% and 49%. The stocks meeting their targets is high for this type of breakout: 75% and 68% percent.

The stock increased 0.07% or $0.0101 during the last trading session, reaching $14.0101. About 8,480 shares traded. Nightstar Therapeutics plc (NASDAQ:NITE) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Nightstar Therapeutics plc (NASDAQ:NITE) to report earnings on July, 3.

More news for Nightstar Therapeutics plc (NASDAQ:NITE) were recently published by: Nasdaq.com, which released: “Nightstar Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference” on April 30, 2018. Nasdaq.com‘s article titled: “Nightstar Therapeutics to Present New Data in Choroideremia at the ARVO 2018 Annual Meeting” and published on April 23, 2018 is yet another important article.

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company has market cap of $404.96 million. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It currently has negative earnings. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy.

Nightstar Therapeutics plc (NASDAQ:NITE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: